serplulimab

Overview

Serplulimab is an investigational anti-PD-1 monoclonal antibody targeting PDCD1. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• Serplulimab listed among anti-PD-1/PD-L1 immune checkpoint inhibitors under investigation for recurrent/metastatic NPC; PD-1/PD-L1 monotherapy ORR approximately 15–20% in NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.